Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
24 avr. 2024 16h01 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
Intra-Cellular Therapies Prices Public Offering of Common Stock
17 avr. 2024 20h46 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
16 avr. 2024 16h06 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
16 avr. 2024 07h00 HE
|
Intra-Cellular Therapies Inc.
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change...
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
19 mars 2024 08h30 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
06 mars 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
27 févr. 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
22 févr. 2024 07h30 HE
|
Intra-Cellular Therapies Inc.
Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million, representing year-over-year growth of 86%. CAPLYTA...
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
08 févr. 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...